Law Firms Set April 7 Deadline for Investors to Lead Inovio Securities Class Action
The filings seek investors to serve as lead plaintiff, a role that guides the case strategy at this early stage.
Overview
- Plaintiff firms, which issued notices Monday, set an April 7, 2026 deadline for Inovio shareholders to seek the lead-plaintiff role in a pending securities case.
- The lawsuit claims Inovio misled investors by downplaying manufacturing problems with its CELLECTRA delivery device for DNA medicines.
- Plaintiffs also allege the company lacked evidence to win fast-track FDA reviews for its INO-3107 application and was unlikely to file the Biologics License Application by late 2024.
- The putative class covers trades from October 10, 2023 through December 26, 2025, and no class has been certified, which means investors are not represented unless they hire a lawyer.
- Notices from the Schall Law Firm, DJS Law Group, Glancy Prongay Wolke & Rotter, and Rosen Law Firm explain that a lead plaintiff represents other investors and helps choose counsel, while non-lead investors may still share in any recovery.